Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.5M | $23.1M | $30.4M | $38.5M | $31.7M | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M |
| Revenue growth | — | -29.0% | 31.9% | 26.5% | -17.7% | 31.8% | 27.5% | 23.0% | 11.7% | 14.4% |
| Gross profit | $26.3M | $17.5M | $23.2M | $29.7M | $23.6M | $32.0M | $41.3M | $50.2M | $56.4M | $64.3M |
| Gross margin | 81.1% | 75.9% | 76.3% | 77.1% | 74.3% | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% |
| Operating income | $10.9M | $1.29M | $6.00M | $8.65M | -$756K | $9.82M | $15.6M | $20.0M | $22.0M | $26.1M |
| Operating margin | 33.6% | 5.6% | 19.7% | 22.5% | -2.4% | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% |
| Net income | $7.21M | $500K | $6.30M | $9.63M | $1.37M | $9.33M | $12.8M | $17.2M | $19.2M | $22.5M |
| Net margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
| EPS (diluted) | $0.60 | $0.04 | $0.52 | $0.78 | $0.11 | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.41M | $3.42M | $7.38M | $10.2M | $5.82M | $11.3M | $10.0M | $13.5M | $25.6M | $24.9M |
| Capital expenditures | $781K | $776K | $228K | $368K | $443K | $482K | $823K | $7.44M | $8.01M | $7.76M |
| Free cash flow | $8.63M | $2.64M | $7.15M | $9.86M | $5.37M | $10.8M | $9.22M | $6.02M | $17.6M | $17.2M |
| Share buybacks | $9.97M | $1.82M | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | $12.6M | $13.2M | $13.7M | $15.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.7M | $18.2M | $28.0M | $43.5M | $50.1M | $62.0M | $58.0M | $49.8M | $52.2M | $51.2M |
| Total assets | $37.2M | $39.0M | $48.4M | $66.7M | $71.1M | $82.9M | $85.5M | $92.2M | $98.3M | $109M |
| Total liabilities | $5.31M | $6.08M | $6.50M | $11.2M | $9.68M | $10.7M | $11.8M | $20.7M | $11.5M | $14.2M |
| Shareholders' equity | $31.9M | $32.9M | $41.9M | $55.5M | $61.4M | $72.2M | $73.7M | $71.4M | $86.8M | $94.6M |
| Retained earnings | $19.9M | $20.4M | $26.7M | $36.3M | $37.7M | $47.0M | $47.3M | $43.3M | $56.8M | $64.2M |
| Shares (wtd avg diluted) | 12.0M | 11.7M | 12.1M | 12.3M | 12.4M | 12.6M | 12.6M | 12.7M | 12.8M | 12.9M |
Every figure is extracted from IRADIMED CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.